Notable product innovations included market approvals in Canada for Simparica Trio and in Japan for Draxxin KP. New diagnostic products like Vetscan® Opticell™ were also introduced, enhancing Zoetis's analytical capabilities. However, safety concerns related to Librela and Solensia require continuous monitoring to ensure the long-term adoption and growth of these key products.